Matwings

Matwings is a South Korean biotechnology company specializing in the development of therapeutics that target the extracellular matrix (ECM), also known as the matrisome. The company utilizes its proprietary Matri-Targeting platform to identify and modulate specific ECM components that drive disease progression in fibrosis and oncology. By focusing on the microenvironment rather than just cellular targets, Matwings aims to overcome limitations of current treatments for hard-to-treat conditions like idiopathic pulmonary fibrosis and desmoplastic solid tumors. Their pipeline includes several pre-clinical candidates designed to remodel the ECM and enhance the efficacy of existing therapies. The company's approach involves using monoclonal antibodies to deliver therapeutic payloads or directly inhibit pathological matrix remodeling.